Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ: AVDL) and Acura Pharmaceuticals (OTCMKTS:ACUR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Profitability

This table compares Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share and Acura Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share 44.47% 33.92% 8.94%
Acura Pharmaceuticals -36.20% -231.18% -31.56%

Valuation and Earnings

This table compares Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share and Acura Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share $150.25 million 2.31 -$41.27 million $1.90 4.56
Acura Pharmaceuticals $4.46 million 1.77 -$7.38 million ($0.14) -2.71

Acura Pharmaceuticals has lower revenue, but higher earnings than Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share. Acura Pharmaceuticals is trading at a lower price-to-earnings ratio than Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, Acura Pharmaceuticals has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share and Acura Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share 0 0 2 0 3.00
Acura Pharmaceuticals 0 0 0 0 N/A

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share presently has a consensus target price of $25.00, indicating a potential upside of 188.35%. Given Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share’s higher possible upside, equities analysts clearly believe Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share is more favorable than Acura Pharmaceuticals.

Institutional and Insider Ownership

67.8% of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share shares are owned by institutional investors. Comparatively, 9.4% of Acura Pharmaceuticals shares are owned by institutional investors. 5.1% of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share shares are owned by insiders. Comparatively, 5.6% of Acura Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share beats Acura Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share Company Profile

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.

Acura Pharmaceuticals Company Profile

Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company’s Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company’s Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company’s Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.

Receive News & Ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share and related companies with Analyst Ratings Network's FREE daily email newsletter.